Formulary Chapter 6: Endocrine system - Full Chapter
06.01.02.03
Other antidiabetic drugs
06.01.02.03
Alpha glucosidase inhibitors
06.01.02.03
DPP4 inhibitors (gliptins)
06.01.02.03
GLP1 agonists
06.01.02.03
Meglitinides
06.01.02.03
SGL2 inhibitors
Canagliflozin
Restricted
Provider notes
NMUH:
This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
NOTE: There is more than one monograph for this medicine, click hereto search for formulary status and its use for other indications.
Provider notes
NMUH:
This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications.
Provider notes
NMUH:
This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
Medicines that should be initiated by a specialist. Prescribing can be transferred to primary care once the patient has been stabilised.
Shared care: For drugs with regular, ongoing need for monitoring and/or assessment of efficacy or toxicity. Prior agreement must be obtained by the specialist from the primary care provider before prescribing responsibility is transferred. The shared care protocol must have been agreed by the relevant secondary care trust Drugs and Therapeutics Committee(s) (DTC) and approved by the North Central London JFC.
Fact sheet: For drugs with some concerns surrounding safety or efficacy but do not require regular monitoring and/or monitoring of effectiveness/toxicity.
Medicines which should normally be prescribed by specialists only (hospital only).
For patients already receiving prescriptions in primary care - continue. No new patients to receive prescriptions in primary care.
Medicines not recommended for routine use in primary or secondary care.
Medicines, which the North Central London JFC has actively reviewed and does not recommend for use at present due to limited clinical and/or cost effective data.
Restricted
